Background. Penicillin allergies are the most commonly reported drug allergies and are documented in up to 17% of patients. Incomplete reaction histories and exaggerated concerns regarding the risk of cross-reactivity often leads to unnecessary avoidance of β-lactams in patients with reported allergies. Utilization of alternative non-β-lactam therapy in patients with reported allergies has been associated with increased incidence of multidrug-resistant organisms, including C. difficile infection. Per the Infectious Diseases Society of America guidelines for implementing an antibiotic stewardship program (ASP), ASPs should promote allergy assessments and penicillin skin testing in patients with a history of a β-lactam allergy. Implementation of penicillin skin testing in the acute care setting is often limited by the education, skill, and time required in administering and interpreting the result. Investigators sought to assess the impact of a β-lactam allergy assessment on aztreonam utilization within a healthcare system.
Background. Aztreonam (AZT) is an alternative antibiotic for Gram-negative infections requiring IV therapy and anti-pseudomonal coverage in patients with an IgE mediated penicillin allergy. However, many reported allergic reactions to penicillins are either unknown or mis-categorized. In 2012, significant use of AZT was observed at our institution coupled with a 29% resistance rate for Pseudomonas aeruginosa (PA) to AZT. The aim of this study was to track and assess AZT use during a 5-year period during which antimicrobial stewardship interventions along with a hospital-wide allergy guideline were implemented to optimize antibiotic use.
Methods. A retrospective review of AZT use was conducted at RUSH University Medical Center from January 2012 to December 2017. September of 2012, AZT was restricted for use in patients with an immediate type-1 hypersensitivity reaction to a β-lactam (BL) with approval from the infectious diseases (ID) consult service. January 2015, a hospital-wide BL allergy guideline, including a clinical pathway for BL graded challenges, was implemented. November 2015 and April 2017, computerized order-sets for BL graded challenges and in-patient penicillin skin tests were executed, respectively. AZT usage was tracked yearly and stratified by the number of patient cases, total number of doses and average days of therapy (DOT) to assess for differences. AZT cost, PA susceptibility, BL graded challenges and ID consultations for approval were also tracked for assessment.
Results. Patient cases using AZT decreased by 76% in 2017. The total number of doses decreased by 84%. The mean DOT for AZT declined from 5.5 days in 2012 to 3.4 days in 2017. The expenditure of AZT reduced by 86%. Hospital-wide resistance rates for PA to AZT declined to 22% in 2017. Compliance with the BL allergy guideline improved post implementation as the number of BL graded challenges rose to a mean of 30 orders with an 82% decrease in ID consults in 2017. Background. Penicillin allergies routinely result in the use of alternative antibiotics, which has shown to increase healthcare cost, length of stay, and the incidence of multi-drug-resistant organisms. The goal of this study was to describe how a pharmacist-managed PAST service could be incorporated into an antimicrobial stewardship program to optimize antimicrobial therapy in patients who report a penicillin allergy and require a penicillin antibiotic.
Methods. The core members trained to conduct a PAST were an Infectious Diseases (ID) physician, ID pharmacist, PGY2 ID pharmacy resident, and five PGY1 pharmacy practice residents. Patients were identified through ID physician consult and/or antimicrobial stewardship team rounds. Patients greater than 18 years old were considered for PAST if they had a history of a type 1, or unknown, allergic reaction to penicillin that occurred greater than 5 years ago and a β-lactam antibiotic was indicated. Patients were excluded for the following reasons: pregnancy, non-type 1 allergic reaction, and recent use of anti-histamines. The primary objective was to reduce the use of alternative antimicrobials such as carbapenems, vancomycin, and fluoroquinolones. Secondary objectives included tolerability of the PAST and β-lactam therapy, and days of alternative antibiotics avoided.
Results. Fifty-eight PASTs were initiated from October 2015 to April 2018. Fifty-six out of 58 (97%) patients completed a PAST. Of the 56 patients that completed a PAST, the negative predictive value was 100%. The most common antibiotics prior to PAST were vancomycin, cefepime, and fluoroquinolones. The most common antibiotics after PAST were penicillin, piperacillin/tazobactam, and amoxicillin/ clavulanate. Bacteremia and skin and soft-tissue infection were the most common indication and Enterococcus and Streptococcus sp. were most frequently isolated. Of the 50 patients that were transitioned to a preferred β-lactam, the number of days of alternative antibiotics avoided ranged from 2 to 180, with a mean of 22.2 days and median of 11 days.
Conclusion. Incorporating a pharmacist-managed PAST service into a community hospital's antimicrobial stewardship program can improve the utilization of preferred antimicrobial therapy and avoid toxic, more costly antimicrobials.
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